Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B73cd958fa4a3de0eeedce23c4b146a4c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B73cd958fa4a3de0eeedce23c4b146a4c NCIT_P378 "NCI" @default.
- B73cd958fa4a3de0eeedce23c4b146a4c type Axiom @default.
- B73cd958fa4a3de0eeedce23c4b146a4c annotatedProperty IAO_0000115 @default.
- B73cd958fa4a3de0eeedce23c4b146a4c annotatedSource NCIT_C151954 @default.
- B73cd958fa4a3de0eeedce23c4b146a4c annotatedTarget "A preparation of genetically modified autologous T-cells transduced with lentiviral vectors expressing chimeric antigen receptors (CARs) specific for the tumor-associated antigens (TAAs) mucin 1 (Muc1; MUC1), cluster of differentiation 33 (CD33), CD38, CD56 and CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-Muc1/CD33/CD38/CD56/CD123 gene-engineered CAR-T cells are directed to and induce selective toxicity in Muc1/CD33/CD38/CD56/CD123-expressing tumor cells. Muc1/CD33/CD38/CD56/CD123 are present on certain tumor cell types and are minimally expressed on normal, healthy cells. Expression of these TAAs are correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules included in the CARs, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity." @default.